Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases
Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited. We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that cou...
Gespeichert in:
| Veröffentlicht in: | Tunisie Medicale 2016-12, Vol.94 (12), p.844-844 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 844 |
|---|---|
| container_issue | 12 |
| container_start_page | 844 |
| container_title | Tunisie Medicale |
| container_volume | 94 |
| creator | Sallami, Sataa Khouni, Hassen Ben Atta, Mahmoud Abou El Makarim, Sana Zouari, Mohamed Bechir Ben Rhouma, Sami |
| description | Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited.
We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that could predict disease recurrence and progression.
Between March 1994 and December 2010, 47 patients (male: 40; female: 7) with median age of 59,5 years (range 40-76 years), diagnosed with bladder CIS underwent weekly BCG instillations (75 mg of Pasteur strain) for six weeks followed by 6 monthly instillations. Patients were collected from four different institututions.Proven bladder CIS diagnosis was made through random biopsy (n=19), macroscopic lesion (n=28) and urinary cytology (n=6).Primary, concomitant, and secondary CIS was found in 13 (27,6%), 28 (59,6%) and 6 (12,7%), patients, respectively.
The median follow up period was 67.5 months (range 60-116 months).The recurence rates were 15,4%, 35,7% and 50% respectively in group I,II and III at 5 years follow-up. The overall complete response rate was 68%.The five-year progression-free survival rate was 87.2%.Several factors, such as age (60 years), gender, previous transurethral resection and type of CIS, were examined by multivariate analysis to predict recurrence and progression. None of them was an independent prognostic factor.Bladder irritation symptoms were the main BCG adverse effects. There were no severe adverse effects requiring discontinuation of drug administration.Radical cystectomy was performed in 5 patients. Extravesical involvement was identified in only one patient. During follow-up period, none died of bladder cancer.
Therapy with BCG is remarkably effective and safe for primary CIS and concomittent CIS, which might be a prognostic factor. We didn't find any significant risk factor. Recurrence and disease progression including extravesical involvement should be carefully monitored over the long-term after BCG therapy. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1949694249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1949694249</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-61ccdfd83ac4cd8c5aebd419e953045ef1ca69f21abe99167dd5e7dd79bb5c5e3</originalsourceid><addsrcrecordid>eNo1kE1OwzAQhbMA0Qp6BeQlm0hx4qQxu6qCglSJDayjsT2hRnYc_APqFbgJ5-BiWKLM4s1ivnlPM2fFsqoYLRlt6KJYhfBW5eoqylt6USzqnnPW982y-Nq76bWM6C1xKUpnkbiR6Cl6-MCgJRgiQGpjUiBbMBZjxHKXfr69nkg8oIf5SD51PBALeQsnmCSS0XmSMgH-SIQBpdATCV7qyVnI7iTomG7JRuRMwtZ5FjBcFecjmICrU78sXu7vnrcP5f5p97jd7MuZ1l0sOyqlGlXfgGRS9bIFFIpRjrxtKtbiSCV0fKwpCOScdmulWsyy5kK0ssXmsrj58529e08Y4mB1kGgMTOhSGChnvOOsZjyj1yc0CYtqmL22-abh_3_NL861cE0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1949694249</pqid></control><display><type>article</type><title>Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Sallami, Sataa ; Khouni, Hassen ; Ben Atta, Mahmoud ; Abou El Makarim, Sana ; Zouari, Mohamed Bechir ; Ben Rhouma, Sami</creator><creatorcontrib>Sallami, Sataa ; Khouni, Hassen ; Ben Atta, Mahmoud ; Abou El Makarim, Sana ; Zouari, Mohamed Bechir ; Ben Rhouma, Sami</creatorcontrib><description>Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited.
We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that could predict disease recurrence and progression.
Between March 1994 and December 2010, 47 patients (male: 40; female: 7) with median age of 59,5 years (range 40-76 years), diagnosed with bladder CIS underwent weekly BCG instillations (75 mg of Pasteur strain) for six weeks followed by 6 monthly instillations. Patients were collected from four different institututions.Proven bladder CIS diagnosis was made through random biopsy (n=19), macroscopic lesion (n=28) and urinary cytology (n=6).Primary, concomitant, and secondary CIS was found in 13 (27,6%), 28 (59,6%) and 6 (12,7%), patients, respectively.
The median follow up period was 67.5 months (range 60-116 months).The recurence rates were 15,4%, 35,7% and 50% respectively in group I,II and III at 5 years follow-up. The overall complete response rate was 68%.The five-year progression-free survival rate was 87.2%.Several factors, such as age (<60 or >60 years), gender, previous transurethral resection and type of CIS, were examined by multivariate analysis to predict recurrence and progression. None of them was an independent prognostic factor.Bladder irritation symptoms were the main BCG adverse effects. There were no severe adverse effects requiring discontinuation of drug administration.Radical cystectomy was performed in 5 patients. Extravesical involvement was identified in only one patient. During follow-up period, none died of bladder cancer.
Therapy with BCG is remarkably effective and safe for primary CIS and concomittent CIS, which might be a prognostic factor. We didn't find any significant risk factor. Recurrence and disease progression including extravesical involvement should be carefully monitored over the long-term after BCG therapy.</description><identifier>ISSN: 0041-4131</identifier><identifier>PMID: 28994883</identifier><language>eng</language><publisher>Tunisia</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Administration, Intravesical ; Adult ; Aged ; BCG Vaccine - administration & dosage ; Carcinoma in Situ - therapy ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Urinary Bladder Neoplasms - therapy</subject><ispartof>Tunisie Medicale, 2016-12, Vol.94 (12), p.844-844</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28994883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sallami, Sataa</creatorcontrib><creatorcontrib>Khouni, Hassen</creatorcontrib><creatorcontrib>Ben Atta, Mahmoud</creatorcontrib><creatorcontrib>Abou El Makarim, Sana</creatorcontrib><creatorcontrib>Zouari, Mohamed Bechir</creatorcontrib><creatorcontrib>Ben Rhouma, Sami</creatorcontrib><title>Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases</title><title>Tunisie Medicale</title><addtitle>Tunis Med</addtitle><description>Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited.
We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that could predict disease recurrence and progression.
Between March 1994 and December 2010, 47 patients (male: 40; female: 7) with median age of 59,5 years (range 40-76 years), diagnosed with bladder CIS underwent weekly BCG instillations (75 mg of Pasteur strain) for six weeks followed by 6 monthly instillations. Patients were collected from four different institututions.Proven bladder CIS diagnosis was made through random biopsy (n=19), macroscopic lesion (n=28) and urinary cytology (n=6).Primary, concomitant, and secondary CIS was found in 13 (27,6%), 28 (59,6%) and 6 (12,7%), patients, respectively.
The median follow up period was 67.5 months (range 60-116 months).The recurence rates were 15,4%, 35,7% and 50% respectively in group I,II and III at 5 years follow-up. The overall complete response rate was 68%.The five-year progression-free survival rate was 87.2%.Several factors, such as age (<60 or >60 years), gender, previous transurethral resection and type of CIS, were examined by multivariate analysis to predict recurrence and progression. None of them was an independent prognostic factor.Bladder irritation symptoms were the main BCG adverse effects. There were no severe adverse effects requiring discontinuation of drug administration.Radical cystectomy was performed in 5 patients. Extravesical involvement was identified in only one patient. During follow-up period, none died of bladder cancer.
Therapy with BCG is remarkably effective and safe for primary CIS and concomittent CIS, which might be a prognostic factor. We didn't find any significant risk factor. Recurrence and disease progression including extravesical involvement should be carefully monitored over the long-term after BCG therapy.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Administration, Intravesical</subject><subject>Adult</subject><subject>Aged</subject><subject>BCG Vaccine - administration & dosage</subject><subject>Carcinoma in Situ - therapy</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Urinary Bladder Neoplasms - therapy</subject><issn>0041-4131</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1OwzAQhbMA0Qp6BeQlm0hx4qQxu6qCglSJDayjsT2hRnYc_APqFbgJ5-BiWKLM4s1ivnlPM2fFsqoYLRlt6KJYhfBW5eoqylt6USzqnnPW982y-Nq76bWM6C1xKUpnkbiR6Cl6-MCgJRgiQGpjUiBbMBZjxHKXfr69nkg8oIf5SD51PBALeQsnmCSS0XmSMgH-SIQBpdATCV7qyVnI7iTomG7JRuRMwtZ5FjBcFecjmICrU78sXu7vnrcP5f5p97jd7MuZ1l0sOyqlGlXfgGRS9bIFFIpRjrxtKtbiSCV0fKwpCOScdmulWsyy5kK0ssXmsrj58529e08Y4mB1kGgMTOhSGChnvOOsZjyj1yc0CYtqmL22-abh_3_NL861cE0</recordid><startdate>201612</startdate><enddate>201612</enddate><creator>Sallami, Sataa</creator><creator>Khouni, Hassen</creator><creator>Ben Atta, Mahmoud</creator><creator>Abou El Makarim, Sana</creator><creator>Zouari, Mohamed Bechir</creator><creator>Ben Rhouma, Sami</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201612</creationdate><title>Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases</title><author>Sallami, Sataa ; Khouni, Hassen ; Ben Atta, Mahmoud ; Abou El Makarim, Sana ; Zouari, Mohamed Bechir ; Ben Rhouma, Sami</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-61ccdfd83ac4cd8c5aebd419e953045ef1ca69f21abe99167dd5e7dd79bb5c5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Administration, Intravesical</topic><topic>Adult</topic><topic>Aged</topic><topic>BCG Vaccine - administration & dosage</topic><topic>Carcinoma in Situ - therapy</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Urinary Bladder Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sallami, Sataa</creatorcontrib><creatorcontrib>Khouni, Hassen</creatorcontrib><creatorcontrib>Ben Atta, Mahmoud</creatorcontrib><creatorcontrib>Abou El Makarim, Sana</creatorcontrib><creatorcontrib>Zouari, Mohamed Bechir</creatorcontrib><creatorcontrib>Ben Rhouma, Sami</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Tunisie Medicale</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sallami, Sataa</au><au>Khouni, Hassen</au><au>Ben Atta, Mahmoud</au><au>Abou El Makarim, Sana</au><au>Zouari, Mohamed Bechir</au><au>Ben Rhouma, Sami</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases</atitle><jtitle>Tunisie Medicale</jtitle><addtitle>Tunis Med</addtitle><date>2016-12</date><risdate>2016</risdate><volume>94</volume><issue>12</issue><spage>844</spage><epage>844</epage><pages>844-844</pages><issn>0041-4131</issn><abstract>Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited.
We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that could predict disease recurrence and progression.
Between March 1994 and December 2010, 47 patients (male: 40; female: 7) with median age of 59,5 years (range 40-76 years), diagnosed with bladder CIS underwent weekly BCG instillations (75 mg of Pasteur strain) for six weeks followed by 6 monthly instillations. Patients were collected from four different institututions.Proven bladder CIS diagnosis was made through random biopsy (n=19), macroscopic lesion (n=28) and urinary cytology (n=6).Primary, concomitant, and secondary CIS was found in 13 (27,6%), 28 (59,6%) and 6 (12,7%), patients, respectively.
The median follow up period was 67.5 months (range 60-116 months).The recurence rates were 15,4%, 35,7% and 50% respectively in group I,II and III at 5 years follow-up. The overall complete response rate was 68%.The five-year progression-free survival rate was 87.2%.Several factors, such as age (<60 or >60 years), gender, previous transurethral resection and type of CIS, were examined by multivariate analysis to predict recurrence and progression. None of them was an independent prognostic factor.Bladder irritation symptoms were the main BCG adverse effects. There were no severe adverse effects requiring discontinuation of drug administration.Radical cystectomy was performed in 5 patients. Extravesical involvement was identified in only one patient. During follow-up period, none died of bladder cancer.
Therapy with BCG is remarkably effective and safe for primary CIS and concomittent CIS, which might be a prognostic factor. We didn't find any significant risk factor. Recurrence and disease progression including extravesical involvement should be carefully monitored over the long-term after BCG therapy.</abstract><cop>Tunisia</cop><pmid>28994883</pmid><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-4131 |
| ispartof | Tunisie Medicale, 2016-12, Vol.94 (12), p.844-844 |
| issn | 0041-4131 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1949694249 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adjuvants, Immunologic - administration & dosage Administration, Intravesical Adult Aged BCG Vaccine - administration & dosage Carcinoma in Situ - therapy Disease Progression Female Follow-Up Studies Humans Male Middle Aged Neoplasm Recurrence, Local Urinary Bladder Neoplasms - therapy |
| title | Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A31%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcome%20of%20intravesical%20bacillus%20Calmette-Gu%C3%A9rin%20therapy%20with%20maintenance%20for%20urinary%20bladder%20carcinoma%20in%20situ:%20About%2047%20cases&rft.jtitle=Tunisie%20Medicale&rft.au=Sallami,%20Sataa&rft.date=2016-12&rft.volume=94&rft.issue=12&rft.spage=844&rft.epage=844&rft.pages=844-844&rft.issn=0041-4131&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1949694249%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1949694249&rft_id=info:pmid/28994883&rfr_iscdi=true |